Академия медицины и спорта. 2021; 2: 23-27
Актуальные вопросы ведения пациентов высокого и очень высокого риска — как добиться максимального эффекта?
https://doi.org/10.15829/2712-7567-2021-19Аннотация
Больные высокого и очень высокого риска сердечно-сосудистых осложнений составляют достаточно большую группу пациентов. В связи с этим своевременное выявление таких пациентов и правильная стратегия их ведения могут существенно снизить частоту сердечно-сосудистых осложнений. Рассматриваются возможности антигипертензивной, липидснижающей и антиагрегантной терапии.
Список литературы
1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013;31(7):1281-357. doi:10.1097/01.hjh.0000431740.32696.cc.
2. Diagnosis and treatment of arterial hypertension. Russian guidelines V revision. Kardiologicheskij Vestnik. 2015;1(10):3-30. Диагностика и лечение артериальной гипертензии. Российские рекомендации V пересмотр. Кардиологический вестник. 2015;1(10):3-30.
3. Chazova IE, Zhernakova YuV, Oshchepkova EV, et al., on behalf of Study articipants. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologia. 2014;10:4-12. (In Russ.) Чазова И. Е., Жернакова Ю. В., Ощепкова Е.В. и др. от имени участников исследования. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4-12. doi:10.18565/cardio.2014.10.4-12.
4. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.
5. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64 Suppl 2:43-60. doi:10.2165/00003495-200464002-00005.
6. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi:10.1136/bmj.b2376.
7. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818. doi:10.1093/eurheartj/ehr158.
8. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian Journal of Cardiology. 2012;(4s1):4-32. (In Russ.) Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российский кардиологический журнал. 2012;(4s1):4-32. doi:10.15829/1560-4071-2012-4s2
9. Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I Ration Pharmacother Cardiol. 2015;11(3):253-60. (In Russ.) Ахмеджанов Н.А., Небиеридзе Д.В., Сафарян А.С. и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I Рациональная Фармакотерапия в Кардиологии. 2015;11(3):253-60. doi:10.20996/1819-6446-2015-11-3-253-260.
10. Antiplatelet Trialist’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
11. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357(9250):89-95. doi:10.1016/s0140-6736(00)03539-x. Erratum in: Lancet. 2001;357(9262):1134.
12. Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.
13. Yusuf S, Sleight P, Pogue J, et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-53. doi:10.1056/NEJM200001203420301. Erratum in: 2000;342(18):1376. Erratum in: N Engl J Med 2000;342(10):748.
14. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-8. doi:10.1016/s0140-6736(03)14286-9.
15. Bönner G, Preis S, Schunk U, et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15 Suppl 6:S46-56.
16. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1991;344(1):126-9. doi:10.1007/BF00167392.
17. Anderson TJ, Overhiser RW, Haber H, Charbonneau F. A comparative study of four antihypertensive agents on endothelial function in patients with coronary disease. J. Am Coll Cardiol. 1998;31 (2, suppl A):32-7A. Abstract.
18. Braunwald E, Domanski MJ, Fowler SE, et al.; PEACE Trial Investigators. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058-68. doi:10.1056/NEJMoa042739.
19. Nissen SE, Tuscu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-26.
20. Diagnosis and treatment of stable angina. Cardiovascular Therapy and Prevention. 2009;1- 43. (In Russ.) Диагностика и лечение стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2009;1-43. doi:10.15829/1728-8800-2009-0-1-43.
21. Lonn EM, Yusuf S, Dzavic V, et al. Effects of ramipril and vitamin E on atherosclerosis: treated with ramipril and vitamin E (SECURE). Circulation. 2001:103:919-25.
22. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87. doi:10.1097/HJH.0b013e3281fc975a. Erratum in: J Hypertens. 2007;25(8):1749.
23. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-9.
24. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcome in hypertensive nephrosclerosis. JAMA. 2001;285:2719-28. doi:10.1001/jama.285.21.2719.
Academy of medicine and sports. 2021; 2: 23-27
Management of high and very high-risk patients — how to achieve the best advantage?
https://doi.org/10.15829/2712-7567-2021-19Abstract
Patients with high and very-high risk of cardiovascular events make up a large group of patients. In this regard, the timely identification of such patients and the correct management can significantly reduce the incidence of cardiovascular events. Potential of antihypertensive, lipid-lowering and antiplatelet therapy are considered.
References
1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013;31(7):1281-357. doi:10.1097/01.hjh.0000431740.32696.cc.
2. Diagnosis and treatment of arterial hypertension. Russian guidelines V revision. Kardiologicheskij Vestnik. 2015;1(10):3-30. Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii V peresmotr. Kardiologicheskii vestnik. 2015;1(10):3-30.
3. Chazova IE, Zhernakova YuV, Oshchepkova EV, et al., on behalf of Study articipants. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologia. 2014;10:4-12. (In Russ.) Chazova I. E., Zhernakova Yu. V., Oshchepkova E.V. i dr. ot imeni uchastnikov issledovaniya. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populyatsii bol'nykh arterial'noi gipertoniei. Kardiologiya. 2014;10:4-12. doi:10.18565/cardio.2014.10.4-12.
4. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.
5. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64 Suppl 2:43-60. doi:10.2165/00003495-200464002-00005.
6. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi:10.1136/bmj.b2376.
7. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818. doi:10.1093/eurheartj/ehr158.
8. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian Journal of Cardiology. 2012;(4s1):4-32. (In Russ.) Diagnostika i korrektsiya narushenii lipidnogo obmena s tsel'yu profilaktiki i lecheniya ateroskleroza. Rossiiskii kardiologicheskii zhurnal. 2012;(4s1):4-32. doi:10.15829/1560-4071-2012-4s2
9. Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I Ration Pharmacother Cardiol. 2015;11(3):253-60. (In Russ.) Akhmedzhanov N.A., Nebieridze D.V., Safaryan A.S. i dr. Analiz rasprostranennosti giperkholesterinemii v usloviyakh ambulatornoi praktiki (po dannym issledovaniya ARGO): chast' I Ratsional'naya Farmakoterapiya v Kardiologii. 2015;11(3):253-60. doi:10.20996/1819-6446-2015-11-3-253-260.
10. Antiplatelet Trialist’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
11. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357(9250):89-95. doi:10.1016/s0140-6736(00)03539-x. Erratum in: Lancet. 2001;357(9262):1134.
12. Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.
13. Yusuf S, Sleight P, Pogue J, et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-53. doi:10.1056/NEJM200001203420301. Erratum in: 2000;342(18):1376. Erratum in: N Engl J Med 2000;342(10):748.
14. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-8. doi:10.1016/s0140-6736(03)14286-9.
15. Bönner G, Preis S, Schunk U, et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15 Suppl 6:S46-56.
16. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1991;344(1):126-9. doi:10.1007/BF00167392.
17. Anderson TJ, Overhiser RW, Haber H, Charbonneau F. A comparative study of four antihypertensive agents on endothelial function in patients with coronary disease. J. Am Coll Cardiol. 1998;31 (2, suppl A):32-7A. Abstract.
18. Braunwald E, Domanski MJ, Fowler SE, et al.; PEACE Trial Investigators. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058-68. doi:10.1056/NEJMoa042739.
19. Nissen SE, Tuscu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-26.
20. Diagnosis and treatment of stable angina. Cardiovascular Therapy and Prevention. 2009;1- 43. (In Russ.) Diagnostika i lechenie stabil'noi stenokardii. Kardiovaskulyarnaya terapiya i profilaktika. 2009;1-43. doi:10.15829/1728-8800-2009-0-1-43.
21. Lonn EM, Yusuf S, Dzavic V, et al. Effects of ramipril and vitamin E on atherosclerosis: treated with ramipril and vitamin E (SECURE). Circulation. 2001:103:919-25.
22. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87. doi:10.1097/HJH.0b013e3281fc975a. Erratum in: J Hypertens. 2007;25(8):1749.
23. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-9.
24. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcome in hypertensive nephrosclerosis. JAMA. 2001;285:2719-28. doi:10.1001/jama.285.21.2719.
